Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Negative Infection Clear all
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 6 Years
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 24, 2026, 6:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
View directory record Official record
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Digital Patient Decision Aid to Increase Sexually Transmitted Infection Testing in the Emergency Department: The STIckER Study

NCT06014177
View directory record Official record
Conditions
STI, Sexually Transmitted Infection (STI), Sexually Transmitted Disease (STD)
Interventions
STIckER, Control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 24 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 24, 2026, 6:10 AM EDT
Completed No phase listed Observational

Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men

NCT02019771
View directory record Official record
Conditions
HIV Infection, Chlamydia, Gonorrhea
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

NCT01113931
View directory record Official record
Conditions
Urogential Chlamydia Trachomatis Infection
Interventions
Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years to 45 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
43
States / cities
Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Home Screening for Chlamydia Surveillance

NCT00177437
View directory record Official record
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
home testing kit
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 29 Years · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 24, 2026, 6:10 AM EDT
Completed No phase listed Observational

Clinical Outcomes and Global Epidemiology -Data Coordinating Center

NCT00524563
View directory record Official record
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

NCT00889967
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin for Inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 24, 2026, 6:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs

NCT03596151
View directory record Official record
Conditions
Chlamydial Infection, Gonorrhoea, Trichomoniasis
Interventions
Click Device
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 24, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

NCT07766980
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy in Children, DMD, Muscular Dystrophy
Interventions
VM100 Nutritional Supplement
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 24, 2026, 6:10 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044
View directory record Official record
Conditions
Dysentery, Diarrhea, Enteric Campylobacteriosis
Interventions
Rifaximin intervention, Placebo intervention
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 24, 2026, 6:10 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Azithromycin in Control of Trachoma II

NCT00286026
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 24, 2026, 6:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM

NCT00187902
View directory record Official record
Conditions
Sexually Transmitted Diseases, Chlamydia, Gonorrhea
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 24, 2026, 6:10 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions
Trumenba Vaccine, MenACWY Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Years to 30 Years
Enrollment
1,307,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 24, 2026, 6:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pathobiomes in Gut of Critically Ill Patients

NCT06822465
View directory record Official record
Conditions
Pseudomonas Aeruginosa
Interventions
P. aeruginosa using in vitro and in vivo assays
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 24, 2026, 6:10 AM EDT
Completed No phase listed Observational

Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia

NCT01140022
View directory record Official record
Conditions
Chlamydia, Screening
Interventions
CT Screening
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 24, 2026, 6:10 AM EDT